ClinicalTrials.gg
Not yet recruitingNCT07661420Updated Oct 7, 2026

211At-MABG in Adults With Advanced Neuroendocrine Cancers

A Phase 1 interventional study of 1 MBq/k of 211At-MABG Fractionated and 2 MBq/k1 of 211At-MABG Fractionated in Pheochromocytoma, Paraganglioma and Neuroendocrine Tumors, sponsored by University of Pennsylvania. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Pennsylvania · Phase 1, Interventional, and Treatment

How we know

Updated Oct 7, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies in Pheochromocytoma with a site in United States — 19 open to participants now, 28 under way, none of them phase 3. Pheochromocytoma · United States.

Planned enrollment
35th of 52
16 · median 31
Started
2026
the only one that year
Phase 1
13 of 69
6 open now
Primary completion
2029-08
later than 17 of 25 live
Registered
67th of 69
by date
Lead sponsor
2 of 69
University of Pennsylvania

Among the 69 studies in Pheochromocytoma with a site in United States, this one is the 35th largest by planned enrollment of the 52 interventional ones that give a count, is the only one that started in 2026, is one of 13 in phase 1, reaches primary completion later than 17 of the 25 other live ones, and was the 67th registered.

Pheochromocytoma

158 studies on the registry are indexed under Pheochromocytoma; 57 are open to participants now.

Browse Pheochromocytoma studies →

Open to participants now

19 of the 69 studies in Pheochromocytoma with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Pheochromocytoma studies recruiting now, 22 (51%) set no upper age limit and 6 (14%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pheochromocytoma with a site in United States, or all of them as a file.
02

Study summary

Phase I dose escalation study of 211At-MABG in adults with advanced pheochromocytoma / paraganglioma (PPGL) or other NET-overexpressing cancers (as evidenced by positive MIBG imaging) who are refractory to, lacking, or ineligible for approved treatments. Phase 1 dose-escalation will follow a standard 3+3 design with an expansion cohort at the recommended phase two dose (RP2D).

03

Conditions studied

  • Pheochromocytoma
  • Paraganglioma
  • Neuroendocrine Tumors
  • Medullary Thyroid Cancer
  • Bronchial Carcinoid
  • Gastroenteropancreatic Neuroendocrine Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients, at least 18 years of age
  2. Advanced neuroendocrine cancers requiring systemic therapy and to, ineligible for, declining, or lacking standard treatments.
  3. I MIBG imaging indicating MIBG-avid disease (radiotracer uptake above background in at least one tumor site) per Investigator/Sub-Investigator assessment.
  4. Participants must provide written prior to study-specific procedures.
  5. performance status ≤ 2.
  6. Adequate organ function including:

    1. ≥ 9 g/dL
    2. ≥ 1,500/mm³
    3. count ≥ 75,000/mm³
    4. Measured or estimated ≥ 60 mL/min
    5. Serum ≤ 1.5x
    6. /AST each ≤ 2.5x upper limit of normal
  7. at least 3 months as judged by treating physician

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breast-feeding will not be eligible for this study.
  2. Inability to tolerate study procedures in the opinion of the investigator or treating physician.
  3. Serious or unstable medical, psychological, or social conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
  4. Uncontrolled (Participant must be at least 4 weeks since CNS-directed therapy and no longer requiring therapy).
  5. Anticancer therapy, except hormonal therapy or bone supportive therapies, within 14 days of cycle 1 day 1.
  6. Has a known additional (other than the disease under study) that has required active systemic treatment within the past 2 years AND for which the natural history or recent/ongoing treatment could likely interfere with study endpoints or safety of the study treatment per Investigator and Medical Director assessment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Dose Level -1: Fractionated 211At-MABG

    One treatment cycle (1 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.25 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).

    Drug: 1 MBq/k of 211At-MABG Fractionated

  • Experimental
    Dose Level 1: Fractionated 211At-MABG

    One treatment cycle (2 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (0.5 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).

    Drug: 2 MBq/k1 of 211At-MABG Fractionated

  • Experimental
    Dose Level 2: Fractionated 211At-MABG

    One treatment cycle (4 MBq/k) of 211At-MABG administered by IV administration in 4 fractionated (1 MBq/kg) weekly doses (+ 7 days) (one treatment cycle = 4 weekly fractionated doses).

    Drug: 4 MBq/k of 211At-MABG Fractionated

Interventions

  • Drug1 MBq/k of 211At-MABG Fractionated

    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)

  • Drug2 MBq/k1 of 211At-MABG Fractionated

    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)

  • Drug4 MBq/k of 211At-MABG Fractionated

    Astatine-211 \[211At\] is a short-lived α emitter conjugated onto meta-astatobenzylguanidine (\[211At\]MABG)

06

What researchers measure

Primary outcomes

  1. Evaluate overall study feasibility

    Proportion of intended 211At-MABG fractionated doses that are successfully administered within the protocol-defined window (at the overall study level).

    Time frame: 4 weeks

  2. Evaluate study feasibility overall study feasibility assessed for operational issues versus treatment-related adverse events.

    Proportion of fractionated dose administrations either delayed and/or omitted due to operational issues (i.e. insufficient/delayed synthesis) versus treatment-related adverse events (at the overall study level).

    Time frame: 4 weeks

Secondary outcomes

  1. Safety of fractionated dosing of 211At-MABG in adults with advanced (PPGL) or other NET-overexpressing cancers per patient level

    The proportion of intended 211At-MABG fractionated doses that are successfully administered within the protocol-defined window assessed at the 'per patient level'.

    Time frame: 4 weeks

  2. Safety of fractionated dosing of 211At-MABG in adults with advanced (PPGL) or other NET-overexpressing cancers per 'dose level'.

    The proportion of intended 211At-MABG fractionated doses that are successfully administered within the protocol-defined window assessed at the 'per dose level'

    Time frame: 4 weeks

  3. The maximum tolerated dose (MTD) and/or Recommended Phase II Dose (RP2D) of 211At-MABG

    Highest dose level at which 0 or 1 DLT occurs in 6 DLT-evaluable subjects

    Time frame: 8 weeks

  4. Incidence of Adverse Events

    Type, frequency, severity, and attribution of adverse events. as assessed by CTCAE version 6.0

    Time frame: 72 months

  5. The objective response rate (ORR) per RECIST 1.1 following a single cycle of fractionated dosing of 211At-MABG

    Proportion of participants with Partial Response (PR) or Complete Response (CR) per RECIST v1.1 criteria

    Time frame: 72 months

  6. The duration of response (DOR) following a single cycle of fractionated dosing of 211At-MABG

    Time from treatment initiation until Progressive Disease (as per RECIST v1.1 criteria) among study participants with PR or CR following a single cycle of fractionated dosing of 211At-MABG

    Time frame: 12 months

  7. The Disease Control Rate (DCR) following a single cycle of fractionated dosing of 211At-MABG

    Proportion of participants with PR or CR or Stable Disease (SD) per RECIST v1.1 criteria following a single cycle of fractionated dosing of 211At-MABG.

    Time frame: 12 months

  8. Biochemical Response (BCR)

    Percent change from baseline in serum or urine metanephrines and catecholamines following a single cycle of fractionated dosing of 211At-MABG

    Time frame: 12 months

  9. Anti-Hypertensive Medication Response

    Change from baseline in anti-hypertensive medication dose following a single cycle of fractionated dosing of 211At-MABG

    Time frame: 12 months

  10. The time to subsequent anti-cancer therapy (time to next treatment) (TTNT)

    time from the first administration of fractionated dose of 211At-MABG until the first administration of subsequent anti-cancer therapy

    Time frame: 12 months

07

Study locations

1 site
  • University of Pennsylvania - Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
    • Abramson Cancer Center · Contact
    • Vivek Narayan, MD, MS · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Aug 2029, 32 months later.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2032
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Aug 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07661420
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2032 (estimated)
Last update
Oct 7, 2026

Study contacts

Abramson Cancer Center
Contact
Vivek Narayan, MD, MS
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion